Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492504 · ClinicalTrials.gov registry record
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,850
- Enrollment target
NCT01492504: Completed study, sponsored by Bristol-Myers Squibb.
NCT01492504 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,850 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01492504 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,850 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) and achieved sustained virologic response.
Primary Outcome
The durability of virologic response, as assessed by the time to loss of virologic response after achieving sustained viral response (SVR12) in a previous study with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052). Loss of virologic response assessed using Hepatitis C virus (HCV) Ribonucleic acid (RNA)
Interventions
- DRUG Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,850 participants |
| Start Date | 2012-02-07 |
| Est. Completion | 2018-03-19 |
What the finished NCT01492504 record still lists
NCT01492504 is an observational study that tracks outcomes without assigning an intervention. Its 1,850 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) is the first listed.
NCT01492504 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01492504 about?
NCT01492504 is a clinical study titled "Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial". The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) and achieved sustained virologic response.
What is the current status of trial NCT01492504?
This trial is currently completed. The enrollment target is 1,850 participants. The study started on 2012-02-07. Estimated completion is 2018-03-19.
What interventions are being tested in trial NCT01492504?
The interventions under investigation include: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) (DRUG).
Who is sponsoring clinical trial NCT01492504?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI